Impact of active smoking on outcomes in HPV+ oropharyngeal cancer.

Authors :: Xiao R
Pham Y
Ward MC
Houston N
Reddy CA
Joshi NP
Greskovich JF Jr
Woody NM
Chute DJ
Lamarre ED
Prendes BL
Lorenz RR
Scharpf J
Burkey BB
Geiger JL
Adelstein DJ
Koyfman SA
Source :: Head & neck [Head Neck] 2020 Feb; Vol. 42 (2), pp. 269-280. Date of Electronic Publication: 2019 Nov 26.
Publication Year :: 2020
Abstract: Background: The role of smoking among patients with human papillomavirus (HPV)-positive oropharyngeal squamous cell carcinoma (OPSCC) is unclear.<br />Methods: A retrospective cohort study of patients with HPV(+) OPSCC from 2001 to 2015 at a tertiary-care institution was conducted. The primary outcome was overall survival (OS).<br />Results: Among 484 included patients, 94 (19.4%) were active smokers, 226 (46.7%) were former smokers, and 164 (33.9%) never smoked. Among active smokers, 82 patients (87.2%) had a ≥10 pack-year and 69 (73.4%) had a ≥20 pack-year smoking history. After adjusting for covariates, active smoking was a significant predictor of inferior OS (HR 2.28, P < .001) and PFS (HR 2.26, P < .001). When including pack-years as the covariate, ≥20 pack-years predicted a decreased effect-size for inferior OS and PFS.<br />Conclusions: For patients with HPV(+) OPSCC, active smoking at diagnosis is the most powerful covariate capturing smoking history to predict OS and PFS.<br /> (© 2019 Wiley Periodicals, Inc.)